Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.72 |
| ▸ | HTR2A | P28223 | 9/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.72 |
| ▸ | DRD3 | P35462 | 3/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.72 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.72 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.72 |
| ▸ | DRD1 | P21728 | 2/20 | 0.72 |
| ▸ | DRD4 | P21917 | 2/20 | 0.72 |
| ▸ | DRD5 | P21918 | 2/20 | 0.72 |
| ▸ | HTR1D | P28221 | 2/20 | 0.72 |
| ▸ | HTR1B | P28222 | 2/20 | 0.72 |
| ▸ | HTR2C | P28335 | 2/20 | 0.72 |
| ▸ | HTR7 | P34969 | 2/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.72 |
| ▸ | HRH1 | P35367 | 2/20 | 0.72 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.72 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.72 |
| ▸ | ACHE | P22303 | 3/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881873 | 0.99 | DRD2 (0.72) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL6885578 | 0.98 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL6881948 | 0.98 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL1958487 | 0.96 | HTR2A (0.73) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL24018542 | 0.93 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL22633920 | 0.93 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| Paliperidone Palmitate SCHEMBL1871384 | 0.93 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL21295308 | 0.93 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL22633922 | 0.93 | HTR2A (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A | |
| SCHEMBL7343354 | 0.93 | DRD2 (0.71) | DRD2HTR2AKCNH2DRD3ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2343296-A1 | A process for the purification of paliperidone | Chemo Ibérica, S.A. (ES) | 2011-07-13 | — | — | EP | claimed |
| WO-2011067220-A1 | A PROCESS FOR THE PURIFICATION OF PALIPERIDONE | CHEMO IBÉRICA, S.A. (ES) | 2011-06-09 | — | — | WO | claimed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-08-28 | — | — | US | disclosed |
| EP-2343296-A1 | A process for the purification of paliperidone | Chemo Ibérica, S.A. (ES) | 2011-07-13 | — | — | EP | disclosed |
| WO-2011067220-A1 | A PROCESS FOR THE PURIFICATION OF PALIPERIDONE | CHEMO IBÉRICA, S.A. (ES) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011042450-A1 | CARRIER LINKED PALIPERIDONE PRODRUGS | ASCENDIS PHARMA AS (DK) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011042453-A1 | SUBCUTANEOUS PALIPERIDONE COMPOSITION | ASCENDIS PHARMA AS (DK) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296257-A1 | High-Loading Water-Soluable Carrier-Linked Prodrugs | ABCB11, SLCO1B1, SLC7A1 | DRD2 3450/4885HTR2A 2385/4885KCNH2 2960/4885 |
| US-20140243254-A1 | Polymeric Hyperbranched Carrier-Linked Prodrugs | P4HA1, CYP8B1, PAH | DRD2 2447/4885HTR2A 1564/4885KCNH2 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.